Compare GOLF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | RYTM |
|---|---|---|
| Founded | 1910 | 2008 |
| Country | United States | United States |
| Employees | 7300 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.8B |
| IPO Year | 2016 | 2017 |
| Metric | GOLF | RYTM |
|---|---|---|
| Price | $86.44 | $101.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $83.67 | ★ $131.14 |
| AVG Volume (30 Days) | 410.5K | ★ 481.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $1,633,721,000.00 | N/A |
| Revenue This Year | $5.76 | $55.34 |
| Revenue Next Year | $2.44 | $86.06 |
| P/E Ratio | $25.14 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $73.09 | $74.50 |
| 52 Week High | $119.65 | $122.20 |
| Indicator | GOLF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 41.15 |
| Support Level | $83.75 | $99.14 |
| Resistance Level | $92.26 | $111.56 |
| Average True Range (ATR) | 2.20 | 4.11 |
| MACD | 0.37 | -1.27 |
| Stochastic Oscillator | 24.82 | 6.89 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.